DOCSLIB.ORG

Dialyzability of Medications During Intermittent Hemodialysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dialyzability of Medications During Intermittent Hemodialysis DialyzeIHD: Dialyzability of Medications During Intermittent Hemodialysis % Dialyzed % Dialyzed % Dialyzed % Dialyzed IHD Dosing; Administration IHD Dosing; Administration IHD Dosing; Administration IHD Dosing; Administration Timing Drug (Type of Drug (Type of Drug (Type of Drug (Type of Timing Around HD Session Timing Around HD Session Around HD Session Dialyzer) Timing Around HD Session Dialyzer) Dialyzer) Dialyzer) 0.25-0.5mg PO Q8H PRN, Insulin Aspart, Pentamidine 0 4mg/kg IV Q24-36H, Not recommended for use, Clonazepam N/A Reduce to 25-50% of normal dose Acarbose N/A Administer anytime during HD Insulin Detemir, Isethionate (N/A) Administer anytime during HD Administer anytime during HD N/A and titrate, Administer anytime Insulin Glargine, 0.1-0.4mg PO Q8-12H, during HD Normal dose and titrate based on 100-150mg PO Q12-24H, <5 Insulin Lispro Acebutolol N/A Clonidine Administer anytime during HD; No target free or corrected total Administer post-HD (Low Flux) Phenytoin Dose post-HD if hypotensive 75-300mg PO Q24H, (Low Flux) phenytoin level, Normal dose based on indication, 0 Administer anytime during HD Acetaminophen N/A 75mg PO Q24H, Irbesartan Administer anytime during HD; Dose Administer anytime during HD Clopidogrel N/A (N/A) Administer anytime during HD post-HD if hypotensive No 15-45mg PO Q24H, Pioglitazone 2.5-5mg/kg IV/PO Q24H, (N/A) Administer anytime during HD 40-60 250-500mg PO Q6H or 1-2g IV Q4- 100mg IV weekly to monthly, Acyclovir Administer post-HD over 60 Cloxacillin N/A Iron Dextran N/A (N/A) 6H, Administer anytime during HD Administer anytime during HD Piperacillin/ 10-65 2.25g-4.5g IV Q12H, minutes Tazobactam (Low Flux) Administer post-HD over 30 minutes Reduce to 50% of normal dose and 100mg IV weekly to monthly, Normal dose based on blood work, Iron Sucrose N/A Alfacalcidol N/A titrate, Administer post -HD Administer anytime during HD 0 Normal dose based on indication, Administer anytime during HD Codeine N/A Posaconazole (if given on HD, may require (N/A) Administer anytime during HD 0.25-0.5mg PO Q8H PRN, supplemental dose post -HD) Isosorbide Minimal 5-40mg PO Q8H, Alprazolam N/A 10-80mg PO Q24H, Administer anytime during HD Dinitrate (N/A) Administer post-HD Pravastatin N/A 22-36.7 Reduce to 75% of normal dose Administer post-HD 2-5 100mg PO Q7days, Cyclophosphamide (over 3- 4 hrs) based on indication, 0 100-200mg PO Q24H, Amantadine (Low Flux) Itraconazole Minimal 1-5mg PO Q8-12H, (Low Flux) Administer anytime during HD Administer post-HD over 20-60 min (High Flux) Administer anytime during HD Prazosin (N/A) Administer anytime during HD Dose based on indication and LD 5-7.5mg/kg IV, then MD 5mg/kg <1 AVOID if possible; 10mg PO Q12H, Cyclosporine target serum level, Normal dose based on indication, 18.5-88 IV QHD (Once daily dosing NOT (Low Flux) Ketorolac N/A Amikacin Administer anytime during HD Administer anytime during HD Prednisone N/A (Low Flux) recommended), Administer post- Administer anytime during HD HD (or over last 10 minutes of HD) 68 AVOID use, 100-400mg PO Q12H, Dabigatran <1 80-160mg PO Q12H, (N/A) Not recommended Labetalol Administer anytime during HD; Dose Propranolol <5 (N/A) Administer anytime during HD; Dose Minimal Normal dose based on indication, (Low Flux) Amiodarone post-HD if hypotensive post-HD if hypotensive (N/A) Administer anytime during HD 100mg PO Q24H, Dapsone N/A Administer anytime during HD 17 Normal dose based on indication, 2.5-10mg PO Q24H, Minimal 2.5-10mg PO Q24H, Lamotrigine 12 Amlodipine (N/A) Administer post-HD Quinapril Administer anytime during HD; Dose (N/A) Administer anytime during HD 6mg/kg IV QHD, (Low Flux) 39-58 post-HD if hypotensive Daptomycin Administer post-HD over 10 30-47 500mg PO Q24H, (High Flux) Normal dose based on blood work, Amoxicillin minutes Lanthanum N/A Yes 200-300mg PO HS or on HD, (Low Flux) Administer post-HD Administer anytime during HD Quinine No (N/A) Administer anytime during HD 0.45mcg/kg/week IV/SC initially, LD 500mg IV/PO, then 250-500mg 0 Normal dose based on indication, Darbepoetin (High & Low 10-21 Amphotericin B Administer anytime during HD Levofloxacin IV/PO Q48H, Administer post-HD Minimal 1.25-5mg PO Q24H, (High Flux) Administer anytime during HD Flux) (High Flux) Ramipril over 60 minutes (Low Flux) Administer post-HD 5mg/kg/week IV, 13-27 0 Dose based on indication, Amphotericin B 0 5mg/kg IV Q24H Deferoxamine Administer post-HD or during last 32-37 600mg IV/PO Q12H, Rituximab (Low Flux) Linezolid (N/A) Administer anytime during HD Lipid Complex (High Flux) Administer anytime during HD hour of HD (Low Flux) Administer post-HD over 30 minutes Normal dose based on indication, 5-40mg PO Q24H, Diazepam N/A 51 2.5-10mg PO Q24-48H, Rosuvastatin N/A 1000mg IV Q12H, Administer anytime during HD Lisinopril Administer anytime during HD 35-40 (Low Flux) Administer post-HD Ampicillin Administer post-HD (Low Flux) AVOID if possible; 25mg PO Q12H, Dose based on blood work, (or last 10 minutes of HD) Diclofenac N/A Reduce to 25-50% of normal dose; Sevelamer N/A Administer anytime during HD Administer anytime during HD Yes Lithium titrate based on target serum level, 50-100 81-325mg PO Q24H (varies based (N/A) ASA LD 0.5-0.75mg (if required), then Administer post-HD Minimal 10-40mg PO Q24H, (N/A) on indication), Administer post-HD Simvastatin Digoxin N/A MD 0.0625mg PO QHD, (N/A) Administer anytime during HD Administer anytime during HD 8 0.5-1mg PO Q8H PRN, 75 25mg PO Q24H, Lorazepam 0 Normal dose based on target serum Atenolol (Low Flux) Administer anytime during HD Sirolimus (Low Flux) Administer post-HD 120-360mg PO Q24H (sustained (N/A) level, Administer anytime during HD Minimal 10-80mg PO Q24H, release), Administer anytime 50-100mg PO Q24H, Atorvastatin Diltiazem N/A 0 Sodium Ferric <1 125mg IV weekly to monthly, (N/A) during HD; Dose post-HD if Losartan Administer anytime during HD; Dose Administer anytime during HD (High Flux) (N/A) Administer anytime during HD hypotensive post-HD if hypotensive Gluconate Reduce to 50% of normal dose 12.5-25mg IV thrice weekly, 45 25-50mg PO/IV/SC Q8H PRN >32 Azathioprine based on indication, Dimenhydrinate N/A 50-70 500-1000mg IV Q24H, Sodium Thiosulfate Administer post-HD over 30-60 (N/A) Administer anytime during HD Meropenem (High Flux) Administer post-HD (Low Flux) Administer post-HD over 15 minutes minutes 25-50mg PO/IV/SC Q6H PRN 250-500mg PO or 500mg IV Q24H, Diphenhydramine N/A Reduce to 50-75% of normal dose 20 40mg PO Q24H, Azithromycin N/A Administer anytime during HD 1-18 Sotalol Administer anytime during HD Methadone and titrate, Administer anytime (low Flux) Administer post-HD (Low Flux) Dose based on indication and during HD LD 1000mg IV, then 500mg IV 1-2g IV Q72-96H, target free valproic acid level, Streptomycin N/A 40 Q12H, 63 AVOID use, Administer post-HD Aztreonam Administer post-HD, if feasible . Methotrexate (Low Flux) Administer post-HD over 20 Divalproex N/A (High Flux) Not recommended minutes For seizure indication, administer Not recommended; 800/160mg Q12H but may require Sulfamethoxazole/ 60 250mg PO Q12-24H, 2-57 (Double Strength tablet) PO or 2.5- Normal dose based on indication, supplemental dose post-HD. Methyldopa Trimethoprim Basiliximab N/A (N/A) Administer post-HD (N/A) 10mg/kg TMP IV daily, Administer Administer anytime during HD (SMX/TMP) 1-8mg PO Q24H, post-HD over 30-60 min Minimal 2.5-5mg PO Q24H, Doxazosin Administer anytime during HD; Methyl- 5-20 Normal dose based on indication, N/A (Low Flux) Normal dose based target serum level, Bisoprolol Dose post-HD if hypotensive prednisolone (N/A) Administer post-HD Tacrolimus N/A Administer post-HD Administer anytime during HD <8 6 100mg IV/PO Q12-24H, Normal dose based on blood work, Doxycycline 5mg PO/IV Q6H, Administer anytime 20-80mg PO Q24H, Calcitriol (High & Low (N/A) Administer anytime during HD 2-51 0 Administer anytime during HD Metoclopramide during HD; (if given on HD, may Telmisartan Administer anytime during HD; Dose Flux) (Low Flux) (N/A) 400mg PO Q12H, require supplemental dose post-HD) post-HD if hypotensive Dronedarone N/A Calcium Normal dose based on blood work, Administer anytime during HD 12.5-200mg Q12H, 15-30mg PO HS PRN, Acetate, As phosphate binder, administer Temazepam N/A N/A 38-57 2.5-10mg PO Q24-48H, Metoprolol N/A Administer anytime during HD; Dose Administer anytime during HD Calcium with meals; As supplementation, Enalapril post-HD if hypotensive (Low Flux) Administer post-HD 1-20mg PO QHS, Carbonate administer post-HD Terazosin N/A No 25-45 500mg IV/PO Q 8-12H, Administer anytime during HD 100units/kg/week IV/SC initially, Metronidazole Normal dose based on blood work Epoetin alfa (High & Low (Low Flux) Administer post-HD over 20 minutes Calcium Administer anytime during HD Not recommended; 125mg PO Q24H, and indication, Flux) Terbinafine N/A Gluconate Likely Yes 100-150mg IV Q24H, Administer anytime during HD Administer anytime during HD; 500mg IV Q24H, N/A Infusion 30 Micafungin Dose post-HD if feasible Ertapenem Administer post-HD over 30 Administer anytime during HD 250-500mg PO Q24H, (N/A) Tetracycline N/A minutes Administer anytime during HD 4-32mg PO Q24H, 2.5-10mg PO PRN intradialytic 0 Yes Candesartan Administer anytime during HD; 0-7 250-500mg PO Q12H, Midodrine hypotension, 0 LD 100mg IV, then 50mg IV Q12H, (High Flux) Erythromycin (N/A) Tigecycline Dose post-HD if hypotensive (Low Flux) Administer anytime during HD Administer at the start of HD (N/A) Administer anytime during HD 40 12.5-50mg PO Q24H, 10mg PO Q24H, Likely 2.5-80mg PO in 1-2 divided doses, LD 2mg/kg IV, then MD 1-1.5mg/kg IV Captopril Ezetimibe N/A Minoxidil (High Flux) (N/A) 50 QHD (Once daily dosing NOT Administer post-HD Administer anytime during HD Administer post-HD Tobramycin (Low Flux) recommended), Administer post-HD Normal dose based on indication, AVOID use, Fenofibrate N/A AVOID if possible; Reduce to 50% of (or last 10 minutes of HD) titrate according to target serum Not recommended 23-51 normal dose and titrate, Administer 9 (Low Flux) level; Administer post-HD, if 0.25-2g PO Q24H, start with low dose Carbamazepine Normal dose based on pain Morphine (High & Low post -HD (if given on HD, may 28 (High Flux) feasible.
Load more

Recommended publications
  • Effects of Acute Intravenous Administration of Pentamidine, a Typical Herg-Trafficking Inhibitor, on the Cardiac Repolarization Process of Halothane-Anesthetized Dogs
    J Pharmacol Sci 110, 476 – 482 (2009)4 Journal of Pharmacological Sciences ©2009 The Japanese Pharmacological Society Full Paper Effects of Acute Intravenous Administration of Pentamidine, a Typical hERG-Trafficking Inhibitor, on the Cardiac Repolarization Process of Halothane-Anesthetized Dogs Hirofumi Yokoyama1,2, Yuji Nakamura1, Hiroshi Iwasaki1, Yukitoshi Nagayama1,2,3, Kiyotaka Hoshiai1,2,3, Yoshitaka Mitsumori1, and Atsushi Sugiyama1,2,* 1Department of Pharmacology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan 2Yamanashi Research Center of Clinical Pharmacology, Fuefuki, Yamanashi 406-0023, Japan 3Sugi Institute of Biological Science, Co., Ltd., Hokuto, Yamanashi 408-0044, Japan Received February 27, 2009; Accepted June 16, 2009 Abstract. Although acute treatment of pentamidine does not directly modify any ionic channel function in the heart at clinically relevant concentrations, its continuous exposure can prolong QT interval. Recent in vitro studies have indicated that hERG trafficking inhibition may play an important role in the onset of pentamidine-induced long QT syndrome. In this study, we examined acute in vivo electropharmacological effects of pentamidine using the halothane- anesthetized canine model (n = 5). The clinically relevant total dose of 4 mg/kg of pentamidine (namely, 1 mg/kg, i.v. over 10 min followed by 3 mg/kg, i.v. over 10 min with a pause of 20 min) decreased the mean blood pressure, ventricular contraction, preload to the left ventricle, and peripheral vascular resistance. Pentamidine also enhanced the atrioventricular conduction in parallel with its cardiohemodynamic actions, but it gradually prolonged both the ventricular repolarization period and effective refractory period, whereas no significant change was detected in the intraventricular conduction.
    [Show full text]
  • Topically Applied Minoxidil in Baldness
    Review Topically Applied Minoxidil in Baldness ERVIN NOVAK,M.D., THOMASJ. FRANZ, M.D., JOHN T. HEADINGTON,M.D., AND RONALD C. WESTER,PH.D. From the Upjohn Company, Kalamazoo, Michigan, School idil and its metabolites can be removed by hemodi- of Medicine, University of Washington, Seattle, alysis. Washington, Medical School, University of Michigan, Ann Fluid retention and hypertrichosis are the most Arbor, Michigan, and School of Medicine and School of Pharmacy, University of California, San Francisco, California commonly occurring side effects of minoxidil. Hair regrowth in a patient with male pattern baldness was described in a case report of a hypertensive patient treated twice daily with 20 mg oral minoxidil.6 The Minoxidil, an orally administered, peripheral va- extensive hair regrowth continued after 10 months sodilator used to treat hypertension, causes hypertri- of therapy. New and increased hair growth as a side chosis in more than 80% of users. The drug reduces effect was also detected in an early clinical study elevated blood pressure by decreasing peripheral involving five of eight patients on oral minoxidil vascular resistance. Chemically, minoxidil is 2,4-di- therapy for 2 month^.^ Zappacosta' reported reversal amino-6-piperidinopyrimidine-3-oxide; it is soluble in of baldness in a patient on minoxidil for the treatment water to the extent of approximately 2 mg/ml, is of hypertension. more readily soluble in propylene glycol or ethanol, After the third week of therapy with oral minoxidil, and is nearly insoluble in acetone, chloroform, or hypertrichosis usually appears between the eyebrows ethyl acetate. Following oral administration of minox- and the hair line, in the malar and temporal areas, idil and in association with the reduction in peripheral on the backs of the arms, on the shoulders, and on vascular resistance, cardiac output is augmented, salt the legs.
    [Show full text]
  • Daily Lifestyle Modifications to Improve Quality of Life And
    brain sciences Review Daily Lifestyle Modifications to Improve Quality of Life and Survival in Glioblastoma: A Review Sarah Travers and N. Scott Litofsky * Division of Neurosurgery, University of Missouri School of Medicine, Columbia, MO 65212, USA; [email protected] * Correspondence: [email protected] Abstract: Survival in glioblastoma remains poor despite advancements in standard-of-care treatment. Some patients wish to take a more active role in their cancer treatment by adopting daily lifestyle changes to improve their quality of life or overall survival. We review the available literature through PubMed and Google Scholar to identify laboratory animal studies, human studies, and ongoing clinical trials. We discuss which health habits patients adopt and which have the most promise in glioblastoma. While results of clinical trials available on these topics are limited, dietary restrictions, exercise, use of supplements and cannabis, and smoking cessation all show some benefit in the comprehensive treatment of glioblastoma. Marital status also has an impact on survival. Further clinical trials combining standard treatments with lifestyle modifications are necessary to quantify their survival advantages. Keywords: survival in glioblastoma; dietary restriction in glioblastoma; cannabis use in glioblastoma; supplementation in glioblastoma; glioblastoma health modifications Citation: Travers, S.; Litofsky, N.S. Daily Lifestyle Modifications to 1. Introduction Improve Quality of Life and Survival Glioblastoma remains the most aggressive and deadly form of primary brain tumor, in Glioblastoma: A Review. Brain Sci. with average survival rates ranging from 7.8 to 23.4 months after diagnosis [1]. Maximal 2021, 11, 533. https://doi.org/ surgical resection followed by radiation and temozolomide have become standard of 10.3390/brainsci11050533 care [2,3].
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Determination of Iodate in Iodised Salt by Redox Titration
    College of Science Determination of Iodate in Iodised Salt by Redox Titration Safety • 0.6 M potassium iodide solution (10 g solid KI made up to 100 mL with distilled water) • 0.5% starch indicator solution Lab coats, safety glasses and enclosed footwear must (see below for preparation) be worn at all times in the laboratory. • 250 mL volumetric flask Introduction • 50 mL pipette (or 20 and 10 mL pipettes) • 250 mL conical flasks New Zealand soil is low in iodine and hence New Zealand food is low in iodine. Until iodised salt was • 10 mL measuring cylinder commonly used (starting in 1924), a large proportion • burette and stand of school children were reported as being affected • distilled water by iodine deficiency – as high as 60% in Canterbury schools, and averaging 20 − 40% overall. In the worst cases this deficiency can lead to disorders such as Method goitre, and impaired physical and mental development. 1. Preparation of 0.002 mol L−1 sodium thiosulfate In earlier times salt was “iodised” by the addition of solution: Accurately weigh about 2.5 g of solid potassium iodide; however, nowadays iodine is more sodium thiosulfate (NaS2O3•5H2O) and dissolve in commonly added in the form of potassium iodate 100 mL of distilled water in a volumetric flask. (This gives a 0.1 mol L−1 solution). Then use a pipette to (KIO3). The Australia New Zealand Food Standards Code specifies that iodised salt must contain: “equivalent to transfer 10 mL of this solution to a 500 mL volumetric no less than 25 mg/kg of iodine; and no more than 65 flask and dilute by adding distilled water up to the mg/kg of iodine”.
    [Show full text]
  • Acne Vulgaris and Intake of Selected Dietary Nutrients—A Summary of Information
    healthcare Review Acne Vulgaris and Intake of Selected Dietary Nutrients—A Summary of Information Aleksandra Podgórska †, Anna Pu´scion-Jakubik*,† , Renata Markiewicz-Zukowska˙ , Krystyna Joanna Gromkowska-K˛epkaand Katarzyna Socha Department of Bromatology, Faculty of Pharmacy with the Division of Laboratory Medicine, Medical University of Białystok, Mickiewicza 2D Street, 15-222 Białystok, Poland; [email protected] (A.P.); [email protected] (R.M.-Z.);˙ [email protected] (K.J.G.-K.); [email protected] (K.S.) * Correspondence: [email protected]; Tel.: +48-8574-854-69 † Contributed equally. Abstract: Acne vulgaris (AV) is a chronic disease that affects a significant percentage of the world’s population. Its development is influenced by both external and internal factors. The purpose of this review is to demonstrate the effect of basic nutrient intake on the exacerbation or alleviation of AV lesions. A retrospective review of publications in PubMed regarding diet therapy and the impact of individual nutrient intake on the skin condition of patients was conducted. Ingestion of products with a high glycaemic index may indirectly lead to sebum overproduction, which promotes infection with Cutibacterium acnes and causes inflammation. Consumption of certain dairy products may result Citation: Podgórska, A.; in skin deterioration caused by the presence of hormones in these products, i.e., progesterone and Pu´scion-Jakubik,A.; testosterone precursors. The beneficial effect of fatty acids on the skin is manifested by the reduction Markiewicz-Zukowska,˙ R.; Gromkowska-K˛epka,K.J.; Socha, K. in inflammation. Of significance in AV treatment are vitamins A, C, D, E and B, as well as mineral Acne Vulgaris and Intake of Selected elements zinc and selenium.
    [Show full text]
  • WHO Model List of Essential Medicines
    WHO Model List of Essential Medicines 15th list, March 2007 Status of this document This is a reprint of the text on the WHO Medicines web site http://www.who.int/medicines/publications/essentialmedicines/en/index.html 15th edition Essential Medicines WHO Model List (revised March 2007) Explanatory Notes The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost‐effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost‐effective treatment. The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost‐effectiveness in a variety of settings. The square box symbol () is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources. Therapeutic equivalence is only indicated on the basis of reviews of efficacy and safety and when consistent with WHO clinical guidelines.
    [Show full text]
  • Vitamin D and Its Analogues Decrease Amyloid- (A) Formation
    International Journal of Molecular Sciences Article Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation Marcus O. W. Grimm 1,2,3,*,† ID , Andrea Thiel 1,† ID , Anna A. Lauer 1 ID , Jakob Winkler 1, Johannes Lehmann 1,4, Liesa Regner 1, Christopher Nelke 1, Daniel Janitschke 1,Céline Benoist 1, Olga Streidenberger 1, Hannah Stötzel 1, Kristina Endres 5, Christian Herr 6 ID , Christoph Beisswenger 6, Heike S. Grimm 1 ID , Robert Bals 6, Frank Lammert 4 and Tobias Hartmann 1,2,3 1 Experimental Neurology, Saarland University, Kirrberger Str. 1, 66421 Homburg/Saar, Germany; [email protected] (A.T.); [email protected] (A.A.L.); [email protected] (J.W.); [email protected] (J.L.); [email protected] (L.R.); [email protected] (C.N.); [email protected] (D.J.); [email protected] (C.B.); [email protected] (O.S.); [email protected] (H.S.); [email protected] (H.S.G.); [email protected] (T.H.) 2 Neurodegeneration and Neurobiology, Saarland University, Kirrberger Str. 1, 66421 Homburg/Saar, Germany 3 Deutsches Institut für DemenzPrävention (DIDP), Saarland University, Kirrberger Str. 1, 66421 Homburg/Saar, Germany 4 Department of Internal Medicine II–Gastroenterology, Saarland University Hospital, Saarland University, Kirrberger Str. 100, 66421 Homburg/Saar, Germany; [email protected] 5 Department of Psychiatry and Psychotherapy, Clinical Research Group, University Medical Centre Johannes Gutenberg, University of Mainz, Untere Zahlbacher Str. 8, 55131 Mainz, Germany; [email protected] 6 Department of Internal Medicine V–Pulmonology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital, Kirrberger Str.
    [Show full text]
  • Positively Selected Modifications in the Pore of Tbaqp2 Allow Pentamidine to Enter
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.08.982751; this version posted March 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Positively selected modifications in the pore of TbAQP2 allow pentamidine to enter 2 Trypanosoma brucei 3 4 Ali H. Alghamdi1, Jane C. Munday1, Gustavo D. Campagnaro1, Dominik Gurvič2, Fredrik 5 Svensson3, Chinyere E. Okpara4, Arvind Kumar ,5 Maria Esther Martin Abril1, Patrik Milić1, 6 Laura Watson1, Daniel Paape,1 Luca Settimo,1 Anna Dimitriou1, Joanna Wielinska1, Graeme 7 Smart1, Laura F. Anderson1, Christopher M. Woodley,4 Siu Pui Ying Kelley1, Hasan M.S. 8 Ibrahim1, Fabian Hulpia6 , Mohammed I. Al-Salabi1, Anthonius A. Eze1, Ibrahim A. Teka1, 9 Simon Gudin1, Christophe Dardonville7, Richard R Tidwell8, Mark Carrington9, Paul M. 10 O’Neill4, David W Boykin5, Ulrich Zachariae2, Harry P. De Koning1,* 11 12 1. Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 13 8TA, UK 14 2. Computational Biology Centre for Translational and Interdisciplinary Research, 15 University of Dundee, Dundee DD1 5EH, UK 16 3. IOTA Pharmaceuticals Ltd, St Johns Innovation Centre, Cowley Road, Cambridge CB4 17 0WS 18 4. Department of Chemistry, University of Liverpool, Liverpool, UK 19 5. Chemistry Department, Georgia State University, Atlanta, GA, US 20 6. Laboratory for Medicinal Chemistry, University of Ghent, Ghent, Belgium 21 7. Instituto de Química Médica - CSIC, Madrid, Spain 22 8.
    [Show full text]
  • Label-Free Cell Phenotypic Profiling Decodes the Composition And
    OPEN Label-free cell phenotypic profiling SUBJECT AREAS: decodes the composition and signaling POTASSIUM CHANNELS SENSORS AND PROBES of an endogenous ATP-sensitive Received potassium channel 28 January 2014 Haiyan Sun1*, Ying Wei1, Huayun Deng1, Qiaojie Xiong2{, Min Li2, Joydeep Lahiri1 & Ye Fang1 Accepted 24 April 2014 1Biochemical Technologies, Science and Technology Division, Corning Incorporated, Corning, NY 14831, United States of Published America, 2The Solomon H. Snyder Department of Neuroscience and High Throughput Biology Center, Johns Hopkins University 12 May 2014 School of Medicine, Baltimore, Maryland 21205, United States of America. Current technologies for studying ion channels are fundamentally limited because of their inability to Correspondence and functionally link ion channel activity to cellular pathways. Herein, we report the use of label-free cell requests for materials phenotypic profiling to decode the composition and signaling of an endogenous ATP-sensitive potassium should be addressed to ion channel (KATP) in HepG2C3A, a hepatocellular carcinoma cell line. Label-free cell phenotypic agonist Y.F. (fangy2@corning. profiling showed that pinacidil triggered characteristically similar dynamic mass redistribution (DMR) com) signals in A431, A549, HT29 and HepG2C3A, but not in HepG2 cells. Reverse transcriptase PCR, RNAi knockdown, and KATP blocker profiling showed that the pinacidil DMR is due to the activation of SUR2/ Kir6.2 KATP channels in HepG2C3A cells. Kinase inhibition and RNAi knockdown showed that the pinacidil * Current address: activated KATP channels trigger signaling through Rho kinase and Janus kinase-3, and cause actin remodeling. The results are the first demonstration of a label-free methodology to characterize the Biodesign Institute, composition and signaling of an endogenous ATP-sensitive potassium ion channel.
    [Show full text]
  • Toiminta Unita on Ulla La Mungukurti |
    TOIMINTAUNITA USON 20180071390A1ULLA LA MUNGUKURTI | ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0071390 A1 PATEL et al. (43 ) Pub . Date : Mar . 15 , 2018 ( 54 ) COMPOSITIONS OF PHARMACEUTICAL A61K 9 / 06 (2006 .01 ) ACTIVES CONTAINING DIETHYLENE A61K 9 /00 (2006 .01 ) GLYCOL MONOETHYL ETHER OR OTHER A61K 31 /573 ( 2006 .01 ) ALKYL DERIVATIVES A61K 31/ 565 ( 2006 .01 ) A61K 31/ 4439 ( 2006 . 01 ) ( 71 ) Applicant : THEMIS MEDICARE LIMITED , A61K 31 / 167 ( 2006 . 01 ) Mumbai (IN ) A61K 31 / 57 (2006 . 01) (52 ) U . S . CI. (72 ) Inventors : Dinesh Shantilal PATEL , Mumbai CPC .. .. .. A61K 47 / 10 ( 2013 . 01 ) ; A61K 9 /4858 ( IN ) ; Sachin Dinesh PATEL , Mumbai ( 2013 .01 ) ; A61K 9 /08 ( 2013 .01 ) ; A61K 9 / 06 ( IN ) ; Shashikant Prabhudas ( 2013 .01 ) ; A61K 9 / 0014 ( 2013 .01 ) ; A61K KURANI, Mumbai ( IN ) ; Madhavlal 31/ 573 ( 2013 .01 ) ; A61K 31 /57 ( 2013 .01 ) ; Govindlal PATEL , Mumbai ( IN ) A61K 31/ 565 ( 2013 .01 ) ; A61K 31 /4439 (73 ) Assignee : THEMIS MEDICARE LIMITED , ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Mumbai (IN ) 9 /0048 ( 2013 .01 ) ; A61K 9 /0019 (2013 .01 ) ( 57 ) ABSTRACT (21 ) Appl. No .: 15 / 801, 390 The present invention relates to pharmaceutical composi tions of various pharmaceutical actives, especially lyophilic ( 22 ) Filed : Nov . 2 , 2017 and hydrophilic actives containing Diethylene glycol mono ethyl ether or other alkyl derivatives thereof as a primary Related U . S . Application Data vehicle and /or to pharmaceutical compositions utilizing (62 ) Division of application No. 14 /242 , 973 , filed on Apr. Diethylene glycol monoethyl ether or other alkyl derivatives 2 , 2014 , now Pat. No. 9 , 827 ,315 .
    [Show full text]
  • Acquired Hypertrichosis of the Periorbital Area and Malar Cheek
    PHOTO CHALLENGE Acquired Hypertrichosis of the Periorbital Area and Malar Cheek Caitlin G. Purvis, BS; Justin P. Bandino, MD; Dirk M. Elston, MD An otherwise healthy woman in her late 50s with Fitzpatrick skin type II presented to the derma- tology department for a scheduled cosmetic botulinum toxin injection. Her medical history was notable only for periodic nonsurgical cosmetic procedures including botulinum toxin and dermal fillers, and she was not taking any daily systemic medications. Duringcopy the preoperative assess- ment, subtle bilateral and symmetric hypertricho- sis with darker terminal hair formation was noted on the periorbital skin and zygomatic cheek. Uponnot inquiry, the patient admitted to purchas- ing a “special eye drop” from Mexico and using it regularly. After instillation of 2 to 3 drops per eye, she would laterally wipe the resulting excess Dodrops away from the eyes with her hands and then wash her hands. She denied a change in eye color from their natural brown but did report using blue color contact lenses. She denied an increase in hair growth elsewhere including the upper lip, chin, upper chest, forearms, and hands. She denied deepening of her voice, CUTIS acne, or hair thinning. WHAT’S THE DIAGNOSIS? a. acetazolamide-induced hypertrichosis b. betamethasone-induced hypertrichosis c. bimatoprost-induced hypertrichosis d. cyclosporine-induced hypertrichosis e. timolol-induced hypertrichosis PLEASE TURN TO PAGE E21 FOR THE DIAGNOSIS From the Department of Dermatology, Medical University of South Carolina, Charleston. The authors report no conflict of interest. Correspondence: Justin P. Bandino, MD, 171 Ashley Ave, MSC 908, Charleston, SC 29425 ([email protected]).
    [Show full text]